Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PRLD
PRLD logo

PRLD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Prelude Therapeutics Inc (PRLD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.450
1 Day change
0.88%
52 Week Range
4.220
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Prelude Therapeutics Inc (PRLD) is not a strong buy at the moment based on the investor's long-term strategy and beginner level. While the stock has potential upside based on analyst ratings and preclinical data, the lack of strong technical signals, weak financial performance, and absence of recent positive news or influential trading activity suggest that it is better to hold off on investing in this stock for now.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating a bearish trend. RSI is neutral at 53.387, and moving averages are converging, suggesting no clear direction. Key support is at 2.917, with resistance at 3.581. The stock is currently trading near its pivot level of 3.249.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
1
Buy
10

Positive Catalysts

  • Analyst from Citizens raised the price target to $6 from $3, citing potential best-in-class selectivity and disease-modifying potential for preclinical JAK2V617F data.

Neutral/Negative Catalysts

  • No significant hedge fund or insider trading activity. Financial performance shows a decline in net income (-42.72% YoY) and EPS (-44.74% YoY). No recent news or congress trading data available.

Financial Performance

In Q4 2025, revenue increased by 41.00% YoY to $5.64M, but net income dropped by 42.72% YoY to -$16.46M. EPS also declined by 44.74% YoY to -0.21. Gross margin remained at 100%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Citizens maintains an Outperform rating and raised the price target to $6, citing meaningful upside potential.

Wall Street analysts forecast PRLD stock price to rise
Analyst Rating
0
Wall Street analysts forecast PRLD stock price to rise
Buy
Hold
Sell
0
Current: 3.450
sliders
Low
0
Averages
0
High
0
0
Current: 3.450
sliders
Low
0
Averages
0
High
0
Citizens
Outperform
maintain
$3 -> $6
AI Analysis
2026-03-11
Reason
Citizens
Price Target
$3 -> $6
AI Analysis
2026-03-11
maintain
Outperform
Reason
Citizens raised the firm's price target on Prelude Therapeutics to $6 from $3 and keeps an Outperform rating on the shares following the Q4 report. The preclinical JAK2V617F data support potential best-in-class selectivity and disease modifying potential, the analyst tells investors in a research note. Citizens believes Prelude shares "represent a unique investment opportunity with meaningful upside."
Citizens JMP
Outperform -> NULL
downgrade
$4 -> $3
2025-08-18
Reason
Citizens JMP
Price Target
$4 -> $3
2025-08-18
downgrade
Outperform -> NULL
Reason
Citizens JMP lowered the firm's price target on Prelude Therapeutics to $3 from $4 and keeps an Outperform rating on the shares. With initial PRT3789 monotherapy data validating the SMARCA2 target, the firm says PRT7732 has a path forward as a combination agent, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PRLD
Unlock Now

People Also Watch